3SBio's (HKG:1530) attributable profit rose 35% to 2.09 billion yuan in 2024 from 1.55 billion yuan in 2023, according to a Tuesday filing with the Hong Kong bourse.
Earnings per share at the biopharmaceutical company increased to 0.85 yuan from 0.62 yuan a year earlier. Analysts at Visible Alpha estimated EPS per share at 0.83 yuan.
Revenue grew 17% to 9.11 billion yuan from 7.82 billion yuan in the previous year. Visible Alpha analysts forecast revenue at 8.90 billion yuan.
The company declared a final dividend of HK$0.25 per share, payable Aug. 15 to shareholders on record as of July 25.